杭州九源基因生物医药股份有限公司(02566)于2026年2月11日发布翌日披露报表，公告公司于当日回购8,600股H股，约占公司回购前已发行股份总数的0.00817%。本次回购价格介乎每股9.89港元至9.90港元，总金额约85,107.9994港元。
回购完成后，公司已发行股份(不包括库存股份)数目变动为105,240,385股，库存股份数目增至3,856,400股。公司亦披露，剩余回购授权基于2025年6月11日通过的议案，授权总数为10,909,678股，此前已回购3,856,400股。
公司在公告中确认，此次回购遵守香港联交所证券上市规则及相关法律规定，相关董事会授权亦已获得正式批准。公告由联席公司秘书黄秀签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.